

3. Survey Component of the CDC's Prevention Marketing Initiative Local Demonstration Site Project Evaluation—NEW—The Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of HIV/AIDS Prevention, Behavioral Intervention Research Branch is planning to conduct a cross-sectional tracking study as part of the evaluation of a five-city HIV prevention demonstration program. The program involves the integration of social marketing strategies and community participation in an effort to develop and implement HIV prevention activities.

Charged with developing programs for those 25 years of age and younger, community groups in the local demonstration sites chose to segment the target audience even further, and to mount a variety of types of interventions. Decisions about segmentation and the nature of local interventions were based on formative research conducted in each community. It is hoped that this demonstration project will result in reductions in HIV risk behavior among members of the target audiences, as well as in enhanced collaboration among individuals and

organizations in the participating communities.

As part of the evaluation of the effectiveness of the interventions, questionnaire data will be collected in three of the demonstration communities. These data will be collected at four time points over a two year period after prevention activities and message campaigns are launched. Baseline survey data have been collected recently under OMB No.0920-0343 (Evaluation of the National AIDS information and Education Program Activities). The total annual burden hours are 4,260.

Respondents	Number of respondents	Number of responses/ respondent	Average burden/response (in hrs.)	Total burden (in hrs.)
Eligibility Screening	157,680	1	0.01667	2,628
Consent	5,768	1	0.05	289
Young People under 25 years of age in targeted prevention program communities	3,504	1	0.3833	1,343

Dated: March 13, 1997.

Wilma G. Johnson,

Acting Associate Director for Policy Planning And Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-6887 Filed 3-18-97; 8:45 am]

BILLING CODE 4163-18-P

Meeting Announcement

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Preventing Birth Defects Due to Thalidomide Exposure.

Time and date: 8 a.m.-5 p.m., March 26, 1997.

Place: Sheraton Colony Square Hotel, 188 14th Street, NE, Atlanta, Georgia 30361.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people. Registration is not required.

Purpose: The meeting will enable academic and public health professionals to discuss strategies to prevent birth defects due to exposure to thalidomide and other human teratogens. Thalidomide, a potent human teratogen, is now available as an investigational drug in the USA. Although the drug is currently being considered for approval only for the treatment of leprosy, its potential applications appear to be numerous. This meeting will bring together leaders from the fields of birth defects research, clinical practice, bioethics, and public health to review existing strategies for limiting intrauterine exposure to human teratogens, and to discuss and provide individual input on new approaches for preventing birth defects due to future teratogens such as thalidomide.

Matters to be discussed: Agenda items will include presentations on the following topics: (1) Assessment of the Accutane Pregnancy Prevention Program, (2) use and limitations of drug registries, (3) contraception efficacy, (4) ethical issues on teratogen exposure, and (5) measures to assure appropriate use of pharmaceuticals. Group discussions on strategies for health care provider education, patient education, and appropriate use of pharmaceuticals will follow the presentations. Written materials may be submitted to CDC until March 21, 1997, for distribution to meeting participants.

Agenda items are subject to change as priorities dictate.

FOR FURTHER INFORMATION
CONTACT: Dwight Jones, Division of Birth Defects and Developmental Disabilities, NCEH, CDC, 4770 Buford Highway, NE, M/ S F-45, Atlanta, Georgia 30341-3724, telephone 770/488-7160, Fax 770/488-7197.

Dated: March 13, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-7017 Filed 3-18-97; 8:45 am]

BILLING CODE 4163-18-P

Food and Drug Administration

Request for Nominations for a Nonvoting Representative of Industry Interests on a Public Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for a nonvoting industry representative to serve on the

Nonprescription Drugs Advisory Committee in the Center for Drug Evaluation and Research. This vacancy will occur on June 1, 1997.

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, the agency encourages nominations of appropriately qualified candidates from these groups.

DATES: Nominations should be received by April 18, 1997.

ADDRESSES: All nominations and curricula vitae for the industry representative should be sent to Andrea G. Neal (address below).

FOR FURTHER INFORMATION CONTACT: Andrea G. Neal, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FAX 301-443-0699.

SUPPLEMENTARY INFORMATION: FDA is requesting that any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interests should send a letter to the contact person (address above). After 30 days, a letter will be sent to each organization that has made a nomination, and to those organizations indicating an interest in participating in the selection process, together with a complete list of all such organizations and the nominees. This letter will state that it is the responsibility of each organization indicating an interest in participating in the selection process to consult with the others in selecting a

single member representing industry interests for the committee within 60 days after receipt of the letter. If no individual is selected within 60 days, the agency will select the nonvoting member representing industry interests. The term of office is 4 years.

Dated: March 13, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97-6848 Filed 3-18-97; 8:45 am]

BILLING CODE 4160-01-F

[Docket Nos. 96N-0421 and 94P-0453]

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled, "Notification of Nutrient Content Claims for Fat or Fatty Acids Based on Digestibility Factors", has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Margaret R. Wolff, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B-19, Rockville, MD 20857, 301-827-1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of December 20, 1996 (61 FR 67243 at 67256), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). OMB has approved the information collection and has assigned OMB control number 0910-0334. The approval expires on February 28, 2000. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

Dated: March 12, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97-6877 Filed 3-18-97; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: March 27, 1997.

Time: 2 p.m.

Place: Parklawn, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857.

Contact Person: Jean G. Noronha, Parklawn, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857; Telephone: 301, 443-6470.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: April 9, 1997.

Time: 8:30 a.m.

Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Jean G. Noronha, Parklawn, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857; Telephone: 301, 443-6470.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle. (Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282.)

Dated: March 14, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-6943 Filed 3-18-97; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Neurological Disorders and Stroke, Division of Extramural Activities; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel.

Date: April 18, 1997.

Time: 8:00 A.M.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Dr. Howard Weinstein, Scientific Review Administrator, National Institutes of Health, 7550 Wisconsin Avenue, Room 9C10, Bethesda, MD 20892, (301) 496-9223.

Purpose/Agenda: To review and evaluate a grant application.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.853, Clinical Research Related to Neurological Disorders; No. 93.854, Biological Basis Research in the Neurosciences).

Dated: March 12, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-6858 Filed 3-18-97; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Dental Research; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Dental Research Special Emphasis Panel (SEP) meeting:

Name of SEP: National Institute of Dental Research Special Emphasis Panel-Contract Review-Amalgam (97-C).

Dates: March 17, 1997.

Time: 3:00 p.m.

Place: National Institutes of Health, 4500 Center Drive, Natcher Building, Room 4AN-44F, Bethesda, MD 20892, (Teleconference).

Contact person: Dr. George Hausch, Chief, Office of Review, 4500 Center Drive, Natcher Building, Room 4AN-44F, Bethesda, MD 20892, (301) 594-2372.

Purpose/Agenda: To evaluate and review contract proposals. This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.121, Oral Diseases and Disorders Research)